An interventional study of Passive neurosensory reintegration training (PNRT) in Mild Traumatic Brain Injury, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Miami · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 420 studies in Brain Concussion with a site in United States — 102 open to participants now, 123 under way, 5 of them phase 3. Brain Concussion · United States.
Among the 420 studies in Brain Concussion with a site in United States, this one is the 136th largest by planned enrollment of the 323 interventional ones that give a count, is one of 27 that started in 2025, is one of 265 with no phase, reaches primary completion later than 35 of the 122 other live ones, and was the 398th registered.
641 studies on the registry are indexed under Brain Concussion; 167 are open to participants now.
Browse Brain Concussion studies →102 of the 420 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
HealthPartners Institute · Sites in United States
Ages 18–65
University of Michigan · Sites in United States
Ages 18+
Perception Dynamics Institute · Sites in United States
Ages 18–60
University of Colorado, Denver · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Brain Concussion studies recruiting now, 34 (30%) set no upper age limit and 73 (64%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
420 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 29 · Phase 3 9 · Phase 4 5
First in 1998; this study’s year is marked. 27 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 63 across 449 interventional studies indexed under Brain Concussion.
Median enrollment 60 across the 323 interventional studies, 147 across the 96 observational. Of the 259 that completed or were terminated, 68 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 420 have an industry lead sponsor. The 10 most frequent:
University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
University of Miami has 5 studies filed under Brain Concussion — fewer than ten, so there is no comparison to draw.
50 of the studies in Brain Concussion with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05320822University of North Carolina, Chapel HillA Pragmatic Rehabilitation Intervention: The Active Rehab Study | 2026-11-28 |
| NCT06109909VA Office of Research and DevelopmentPilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury | 2026-11-30 |
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT04708613David Okonkwo, MD, PhDUniversity of Pittsburgh Brain Health Initiative | 2026-12 |
Add all 50 to your calendar (.ics) → With an account.
Among the 420 studies in Brain Concussion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mild traumatic brain injury (mTBI) poses a substantial clinical and public health burden, often leading to persistent neurosensory and cognitive symptoms for which diagnostic and therapeutic solutions remain limited. This study proposes a multimodal diagnostic framework that integrates established mTBI screening tools and clinical neuro-optometric assessments with high-resolution oculomotor, vestibular, and reaction time (OVRT) testing to enhance diagnostic precision and identify prognostic markers of recovery. Normative data will be established in healthy controls to inform objective thresholds and support clinical implementation. Concurrently, we will evaluate the safety, tolerability, and preliminary efficacy of a novel, minimal-risk multisensory therapeutic intervention (i.e., passive neurosensory reintegration training, or PNRT) for individuals with sub-acute or chronic mTBI. By addressing critical gaps in both diagnosis and treatment, this project will improve mTBI recovery outcomes, inform future clinical trials, and advance evidence-based mTBI care guidelines.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of diagnosed psychiatric disorder or /rheumatologic conditions prior to brain injury
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Passive Neurosensory Reintegration Training (PNRT), a multisensory neuromodulation protocol integrating synchronized visual, vestibular, auditory, and somatosensory inputs to promote sensory reintegration and recovery of balance and oculomotor function. Each participant will complete 12 sessions over approximately two weeks (Days 1-12). Each session lasts approximately 60 minutes and involves exposure to coordinated low-intensity light, motion, and auditory stimuli in a controlled seated position. Participants will complete standardized assessments at Baseline, Day 6 (midpoint), Day 13 (post-intervention), and Day 40 (follow-up).
Device: Passive neurosensory reintegration training (PNRT)
Participants assigned to the control arm will receive no active intervention during the initial 13-day period. They will undergo the same schedule of baseline, midpoint (Day 6), post (Day 13), and follow-up (Day 40) assessments as the PNRT group.
PNRT is a non-invasive, device-based system that delivers synchronized visual, vestibular, auditory, and somatosensory stimulation. The system consists of a light box and motion platform. Participants remain supine while receiving filtered halogen light at \<10 lux intensity (non-laser, non-UV) synchronized with controlled stimuli.
Change in Dizziness Handicap Inventory (DHI) Total Score
Change in DHI total score from baseline to Day 13 following Passive Neurosensory Reintegration Training (PNRT). The mean change will be reported with 95% confidence intervals. Additionally, the proportion of participants achieving ≥18-point reduction in DHI score will be calculated as having clinically meaningful improvement.
Time frame: Baseline to Day 13 (Post-Intervention)
Change in the Number of Abnormal I-PAS Oculomotor Metrics
Change from baseline in the number of I-Portal Portable Assessment System (I-PAS) oculomotor metrics outside normative reference intervals derived from the healthy control group. Metrics assessed include pursuit gain, gain asymmetry, inward/outward step gain, eye correlation, and saccadic intrusions.
Time frame: Baseline to Day 13 (Post-Intervention)
Change in SCAT-6 Symptom Severity
Change from baseline in concussion symptom severity as assessed by the Sport Concussion Assessment Tool, 6th Edition (SCAT-6). The Symptom Severity Score is calculated as the sum of 22 symptom ratings, each scored from 0 (none) to 6 (severe), for a total score ranging from 0 to 132. Higher scores indicate greater symptom burden.
Time frame: Baseline to Day 13 (Post-Intervention)
Percentage of Participants Meeting Responder Criteria
Participants with at least one I-Portal Portable Assessment System (I-PAS) parameter outside normative reference intervals at Baseline. A responder is defined as a participant who has at least one baseline-abnormal parameter that returns to within normative reference intervals at Day 13. Reported as the percentage of participants meeting responder criteria.
Time frame: Baseline to Day 13 (Post-Intervention)
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in publications may be made available to qualified researchers upon reasonable request, following publication of primary study results.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 249 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 265 studies reached it within 28 months; a quarter within 19 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.